FN2 Earnings Intelligence

Teva Pharmaceutical Industries Limited earnings overview

Latest Teva Pharmaceutical Industries Limited (TEVA) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportTeva Pharmaceutical Industries Limited reports Tuesday, Nov 3, 2026 · Before market openConsensus EPS $0.72 · consensus revenue $4.23B
TEVA FY2026 Q3 · Calendar Q4 2026

Teva Pharmaceutical Industries Limited

Teva’s shift toward innovative medicines and biosimilars is showing growth and margin progress, supporting a higher full-year revenue outlook despite a decline in total Q3 revenue. Sustaining that progress depends on launch execution, payer access, and managing pricing pressure.

EPS surprise—
Market move+3.3%

Get the TEVA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.